Shares of Alere fell about 3 percent Friday after it sued Abbott Laboratories to compel the healthcare company to get U.S. antitrust approvals required to complete its $5.8 billion deal to acquire Alere.
In a statement, Abbott spokeswoman Darcy Ross said, “Alere’s lawsuit is without merit. Abbott is compliant with its obligations under the merger agreement and continues to work toward regulatory approvals, despite Alere’s nearly six month delay in filing its 2015 10-K.”
